Antman K, Pass H, Schiff P: Benign and malignant meosthelioma. In Cancer: Principles and Practice of Oncology, edn 5. Edited by DeVita VT, Hellman S, Rosenberg, SA. Philadelphia: Lippincott-Raven Publishers; 1997:1853–1878.
Kindler H, Vogelzang N: Mesothelioma. In Oncologic Therapies. Edited by Vokes E, Golomb H. Berlin: Springer-Verlag; 1999:635.
Baas P, Schouwink H, Zoetmulder FA: Malignant pleural mesothelioma. Ann Oncol 1998, 9:139–149.
Carbone M, Pass HI, Rizzo P, et al.: Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 1994, 9:1781–1790.
Rizzo P, Bocchetta MK, Pass H, et al.:SV40 and the pathogenesis of mesothelioma. Semin Cancer Biol 2001, 11:63–71.
Jasani B, Jones CJ, Radu C, et al.: Simian virus 40 detection in human mesothelioma: reliability and significance of the available molecular evidence. Front Biosci 2001, 6:E12-E22.
Sterman DH, Kaiser LR, Albelda SM: Advances in the treatment of malignant pleural mesothelioma. Chest 1999, 116:504–520. This is a comprehensive review of emerging treatments for mesothelioma.
Sugarbaker DJ, Norberto JJ, Swanson SJ: Extrapleural pneumonectomy in the setting of multimodality therapy for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 1997, 9:373–382.
Maggi G, Casadio C, Cianci R, et al.: Trimodality management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2001, 19:346–350.
Byrne MJ, Davidson JA, Musk AW, et al.: Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999, 17:25–30.
Kindler HL, Millard F, Herndon JE, et al.: Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001, 31:311–317.
Oh Y, Perez-Soler R, Fossella FV, et al.: Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs 2000, 18:243–245.
Ong ST, Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996, 14:1007–1017.
Vogelzang NJ, Goutsou M, Corson JM, et al.: Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990, 27:239–242.
Chahinian AP, Antman K, Goutsou M, et al.: Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993, 11:1559–1565.
Stam TC, Swaak AJ, Kruit WH, et al.: Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response. Eur J Clin Invest 2000, 30:336–343.
Figlin R, Mendoza E, Piantadosi S, Rusch V: Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. Chest 1994, 106:363S-366S.
Kindler H: Malignant pleural mesothelioma. Curr Treat Opt Oncol 2000, 1:313–326.
Davis SR, Tan L, Ball DL: Radiotherapy in the treatment of malignant mesothelioma of the pleura, with special reference to its use in palliation. Australas Radiol 1994, 38:212–214.
Gomer C, Dougherty T: Determination of [3H]- and [14C] hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res 1979, 39:146–151.
Young SW, Woodburn KW, Wright M, et al.: Lutetium texaphyrin (PCI-0123) a near-infrared, water-soluble photosensitizer. Photochem Photobiol 1996, 63:892–897.
Berenbaum MC, Akande SL, Bonnett R, et al.: Meso-Tetra(hydroxyphenyl)porphyrins, a new class of potent tumour photosensitisers with favourable selectivity. Br J Cancer 1986, 54:717–725.
DoughertyTJ, Gomer CJ, Henderson BW, et al.: Photodynamic therapy [review]. J Natl Cancer Inst 1998, 90:889–905. This is an excellent comprehensive review, detailing the scientific, clinical, and technical aspects of PDT.
Pass HI: Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 1993, 85:443–456.
Foote CS: Mechanisms of photooxygenation. Prog Clin Biol Res 1984, 170:3–18.
Gomer CJ, Rucker N, Banerjee A, et al.: Comparison of mutagenicity and induction of sister chromatid exchange in Chinese hamster cells exposed to hematoporphyrin derivative photoradiation, ionizing radiation, or ultraviolet radiation. Cancer Res 1983, 43:2622–2627.
Hahn S, Glatstein E: The emergence of photodynamic therapy as a major modality in cancer treatment. Rev Contemp Pharmocother 1999, 10:69–74.
Murrer L, Marijnissen J, Baas P, et al.: Applicator for light delivery and in situ light dosimetry during endobronchial photodynamic therapy: first measurements in humans. Lasers Med Sci 1997, 12:253–259.
Tan IB, Oppelaar H, Ruevekamp MC, et al.: The importance of in situ light dosimetry for photodynamic therapy of oral cavity tumors. Head Neck 1999, 21:434–441.
Baas P, Murrer L, Zoetmulder FA, et al.: Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 1997, 76:819–826. This study reports a clinical trial of Foscan mediated PDT for pleural malignancies. A novel light dosimetry system is discussed.
Ris H, Altermatt H, Nachbur B, et al.: Intraoperative photodynamic therapy with m-tetrahydroxyphenylchlorin for chest malignancies. Lasers Surg Med 1996, 18:39–45.
Wieman T, Panella T, Lustig R, et al.: Photodynamic therapy (PDT) of locally recurrent breast cancer (LRBC) with lutetium texaphyrin (Lutrin): a phase IB/IIA trial [abstract]. Proc ASCO 1999, 18:111a.
Yuen A, Panella T, Wieman T, et al.: Phase I trial of photodynamic therapy with lutetium-texaphyrin (LU-TEX) [abstract]. Proc ASCO 1997, 16:219a.
Sugarbaker DJ, Mentzer SJ, Strauss G: Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Thorac Surg 1992, 54:941–946. An excellent report that provides the details of the surgical treatment of mesothelioma.
Takita H, Mang TS, Loewen GM, et al.: Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study. Ann Thorac Surg 1994, 58:995–998.
Moskal TL, Dougherty TJ, Urschel JD, et al.: Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann Thorac Surg 1998, 66:1128–33.
Pass HI, DeLaney TF, Tochner Z, et al.: Intrapleural photodynamic therapy: results of a phase I trial. Ann Surg Oncol 1994, 1:28–37. This is a report of a well-designed and performed phase I trial of Photofrin mediated PDT.
PassHI, Temeck BK, Kranda K, et al.: Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997, 4:628–633. This is a report of the only randomized phase III trial of PDT for the treatment of mesothelioma.
Ris HB, Altermatt HJ, Inderbitzi R, et al.: Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer 1991, 64:1116–1120.
Kindler H, Vogelzang N, Chien K, et al.: SU5416 in malignant mesothelioma: a university of chicago phase II consortium study [abstract]. Proc ASCO 2001, 20:341a.
Ferrario A, von Tiehl KF, Rucker N, et al.: Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000, 60:4066–4469.
Dimitroff CJ, Klohs W, Sharma A, et al.: Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 1999, 17:121–135.
Boutin C, Viallat JR, Van Zandwijk N, et al.: Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991, 67:2033–2037.
Korbelik M, Dougherty GJ: Photodynamic therapymediated immune response against subcutaneous mouse tumors. Cancer Res 1999, 59:1941–1946.
Korbelik M, Cecic I: Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett 1999, 137:91–98.
Korbelik M: Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 1996, 14:329–334.
Korbelik M, Cecic I: Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment. J Photochem Photobiol B 1998, 44:151–158.
Korbelik M, Sun J, Posakony JJ: Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors. Photochem Photobiol 2001, 73:403–409.
Korbelik M, Naraparaju VR, Yamamoto N: Macrophagedirected immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 1997, 75:202–207.